Veloxis Pharmaceuticals

Reporting of Managers' and Closely Associated Persons' Transactions in Veloxis-Shares and Financial Instruments Linked Hereto

Company Release no. 5/2020

To: NASDAQ Copenhagen A/S                                    

Copenhagen, Denmark, 15 January 2020

 

Veloxis Pharmaceuticals: Reporting of Managers' and Closely Associated Persons' Transactions in Veloxis-Shares and Financial Instruments Linked Hereto

 

Today, Veloxis Pharmaceuticals A/S (OMX: VELO) ("Veloxis") announces the attached reporting of transactions in Veloxis-shares and financial instruments linked hereto made by managers as well as persons closely associated with them, pursuant to Article 19(3) of EU Regulation 596/2014 of 16 April 2014 on market abuse (market abuse regulation).

The sale of shares and warrants mentioned in the attached reporting relates to completion of the recommended voluntary public offer made by Asahi Kasei Pharma Denmark A/S, please refer to company release no. 3/2020.

 

For more information, please contact:

Craig A. Collard             Ira Duarte                               
CEO                              CFO     

Phone:                         [phone]       
Email:                           [e-mail]

This announcement has been prepared both in English and Danish. In the event of any discrepancies between the English and Danish version, the English version shall prevail.

 

Attachments:

Notifications pursuant to Article 19(3) of the Market Abuse Regulation

 

About Veloxis

Veloxis is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit www.veloxis.com.